Loading clinical trials...

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Clinical Trials | Clareo Health

Not Yet RecruitingPhase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

NCT07421167•Novartis Pharmaceuticals

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)

Interventions

ianalumab

thrombopoietin receptor agonist (TPO-RA)

Key Dates

Start Date

June 30, 2026

Primary Completion Date

June 9, 2028

Completion Date

March 13, 2030

Last Updated

April 2, 2026

Related Studies

RECRUITINGEARLY Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

NCT06888960

Systemic Lupus Erythematosus (SLE)Idiopathic Inflammatory Myopathy (IIM)+4 more

Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe

NCT06408324

Primary Immune Thrombocytopenia (ITP)

Contacts

Novartis Pharmaceuticals

CONTACT

1-888-669-6682 novartis.email@novartis.com

Novartis Pharmaceuticals

CONTACT

+41613241111 novartis.email@novartis.com

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 2, 2026Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions